Citigroup Inc. Purchases 15,348 Shares of Sanofi (NASDAQ:SNY)

Citigroup Inc. lifted its position in shares of Sanofi (NASDAQ:SNY) by 2.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 631,672 shares of the company’s stock after acquiring an additional 15,348 shares during the period. Citigroup Inc.’s holdings in Sanofi were worth $36,403,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in SNY. Raymond James Trust N.A. lifted its stake in Sanofi by 4.0% during the 3rd quarter. Raymond James Trust N.A. now owns 55,200 shares of the company’s stock valued at $3,181,000 after acquiring an additional 2,120 shares during the period. Eagle Asset Management Inc. raised its holdings in shares of Sanofi by 11.1% during the third quarter. Eagle Asset Management Inc. now owns 6,582 shares of the company’s stock valued at $379,000 after purchasing an additional 658 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Sanofi by 31.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after purchasing an additional 33,105 shares during the period. Banco Santander S.A. boosted its holdings in Sanofi by 4.4% in the third quarter. Banco Santander S.A. now owns 38,066 shares of the company’s stock worth $2,194,000 after purchasing an additional 1,604 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in Sanofi by 4.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 147,955 shares of the company’s stock worth $8,527,000 after purchasing an additional 6,796 shares during the period. Institutional investors own 10.04% of the company’s stock.

Sanofi Trading Up 0.6 %

NASDAQ:SNY opened at $48.28 on Monday. Sanofi has a one year low of $45.22 and a one year high of $58.97. The business has a fifty day moving average price of $53.70 and a 200-day moving average price of $52.18. The firm has a market capitalization of $122.53 billion, a price-to-earnings ratio of 24.63, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The business’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same quarter last year, the company earned $2.55 earnings per share. Sell-side analysts forecast that Sanofi will post 4.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SNY. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.